Medscape

Tree Pollen Sensitization Varies by Sex and Geography

Tree pollen sensitization varies by sex, age, diagnoses of atopic conditions, urbanization, and ecoregion in the US, a study ...
The Manila Times

Colostrum Supplements for Weight Loss: How Consumers Compare IgG Potency, Gut Health Claims, and Sourcing Standards in 2026

As Searches for 'Best Colostrum Supplement for Weight Loss' Rise, Cowboy Colostrum Emerges as One Example Consumers Are ...

Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases

Annexon (ANNX) stock: high-risk biotech upside from tanruprubart (GBS) & vonaprument (geographic atrophy). Read here for a ...

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI ® (ublituximab-xiiy), to be presented (ACTRIMS) annual forum, being held February 5 – ...
The Malaysian Reserve

DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible

Quadruplet regimen demonstrated significantly deeper and more durable responses, higher MRD negativity and improved progression-free survival versus a ...
Renal & Urology News

FDA Extends Review of Sparsentan for Focal Segmental Glomerulosclerosis

The Food and Drug Administration has extended the review period for sparsentan in focal segmental glomerulosclerosis (FSGS).
The American Journal of Managed Care

Ocular Symptoms, Malignancy Common in Double Seronegative MG

Patients with double seronegative myasthenia gravis (dSNMG) had similar clinical characteristics across the board, according to a review published in BMC Neurology. 1 Ocular symptoms and malignancy ...
PharmiWeb

Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings

The D-Domain binder has a fast off-rate and contributes to anito-cel’s differentiated pharmacology profile in multiple myeloma ---- A simulation model of CAR T use ahead of bispecific antibodies in ...
TMCnet

FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under ...

LEQEMBI is currently approved in 53 countries and regions and is under regulatory review in 7 countries. In August 2025, the US FDA approved LEQEMBI IQLIK 360 mg for weekly subcutaneous maintenance ...
BMJ Open

Prognostic factors for mortality in patients infected with New World hantaviruses: a systematic review and meta-analysis

Introduction One of the challenges in managing patients with hantavirus infection is accurately identifying individuals who are at risk of developing severe disease. Prompt identification of these ...

Biogen Inc.: FDA Accepts LEQEMBI IQLIK (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's ...

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA acti ...
Le Lézard

Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab

Agenus Inc. , a leader in immuno-oncology innovation, today announced the expansion of its global Medical Affairs infrastructure and early-access support capabilities in response to increasing ...